Gujarat Themis Biosyn Ltd Stock Price Today (NSE: GUJTHEM)
Fundamental Score
Gujarat Themis Biosyn Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Gujarat Themis Biosyn Ltd share price today is ₹379.85, up +0.33% on NSE/BSE as of 17 June 2026. Gujarat Themis Biosyn Ltd (GUJTHEM) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹4.45K (Cr). The 52-week high for GUJTHEM share price is ₹479.00 and the 52-week low is ₹225.05. At a P/E ratio of 92.24x, GUJTHEM is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 21.69% and a debt-to-equity ratio of 0.27.
Gujarat Themis Biosyn Ltd Share Price Chart — NSE/BSE Historical Performance
Gujarat Themis Biosyn Ltd share price chart: 20.57% return over the past month. 52-week high ₹479.00, 52-week low ₹225.05.
Gujarat Themis Biosyn Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹401.10 | ₹401.10 | ₹387.90 | ₹395.00 | 78.85K (Cr) | |
| ₹404.30 | ₹412.00 | ₹389.75 | ₹398.80 | 1.63L (Cr) | |
| ₹429.05 | ₹429.05 | ₹400.00 | ₹404.30 | 3.50L (Cr) | |
| ₹367.65 | ₹441.20 | ₹366.00 | ₹432.20 | 28.87L (Cr) | |
| ₹385.00 | ₹385.40 | ₹362.05 | ₹367.70 | 2.73L (Cr) | |
| ₹379.00 | ₹401.90 | ₹377.00 | ₹389.35 | 6.80L (Cr) | |
| ₹366.95 | ₹372.00 | ₹359.05 | ₹368.70 | 1.60L (Cr) | |
| ₹358.00 | ₹361.40 | ₹354.05 | ₹357.10 | 56.94K (Cr) | |
| ₹365.00 | ₹365.00 | ₹353.25 | ₹355.60 | 79.55K (Cr) | |
| ₹352.60 | ₹371.00 | ₹350.10 | ₹356.25 | 1.12L (Cr) |
Gujarat Themis Biosyn Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹404.30 | ₹412.00 | ₹387.90 | ₹395.00 | -2.30% | |
| ₹365.00 | ₹441.20 | ₹336.90 | ₹404.30 | +10.77% | |
| ₹239.99 | ₹383.99 | ₹234.00 | ₹363.58 | +51.50% | |
| ₹285.00 | ₹306.80 | ₹225.05 | ₹226.90 | -20.39% | |
| ₹325.05 | ₹354.00 | ₹301.30 | ₹308.30 | -5.15% | |
| ₹441.65 | ₹445.00 | ₹305.00 | ₹323.10 | -26.84% | |
| ₹411.00 | ₹457.80 | ₹362.65 | ₹441.65 | +7.46% | |
| ₹465.10 | ₹471.80 | ₹397.70 | ₹407.60 | -12.36% | |
| ₹397.90 | ₹479.00 | ₹385.05 | ₹465.10 | +16.89% | |
| ₹378.20 | ₹424.90 | ₹373.00 | ₹394.75 | +4.37% | |
| ₹393.30 | ₹410.00 | ₹336.85 | ₹378.20 | -3.84% | |
| ₹351.60 | ₹401.80 | ₹340.00 | ₹391.45 | +11.33% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Gujarat Themis Biosyn Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Gujarat Themis Biosyn Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of GUJTHEM across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (21.69%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (27.29%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (47.49%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (34.91%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (21.98%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (12.12% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (16.18% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (16.17% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.27)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (222.97x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (70.86%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Risk Factors
2 factors identified
Premium Valuation Risk (P/E: 92.24x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Limited Institutional Interest (FII+DII: 4.12%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Gujarat Themis Biosyn Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Gujarat Themis Biosyn Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Gujarat Themis Biosyn LtdGujarat Themis ...Selected✓ GUJTHEM • 506879 | 68.9/100 | ₹379.85₹380 | ₹4454.49₹4454.49 | 92.24Average 92.2 Average | 21.69%Excellent 21.69% Excellent | 27.29%Excellent 27.29% Excellent | 0.27Excellent 0.3 Excellent | 16.17%Excellent 16.17% Excellent | 12.12%Good 12.12% Good | 0.16% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Gujarat Themis Biosyn Ltd PE Ratio History
Historical price-to-earnings ratio for GUJTHEM — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹4.48 | ₹441.65 | 98.6x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Gujarat Themis Biosyn Ltd Dividend History
Annual cash dividends paid by GUJTHEM — dividend yield 0.16%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹1.82 Cr |
| FY 2024 | ₹6.90 Cr |
| FY 2023 | ₹12.44 Cr |
| FY 2022 | ₹10.00 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Gujarat Themis Biosyn Ltd Quarterly Performance
Latest quarterly metrics for GUJTHEM — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
21.98%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
34.91%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
12.12%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
16.17%
Compounded annual net profit growth over 5 years
Gujarat Themis Biosyn Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for GUJTHEM — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Gujarat Themis Biosyn Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Gujarat Themis Biosyn Ltd (GUJTHEM) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Gujarat Themis Biosyn Ltd
About GUJTHEM (Gujarat Themis Biosyn Ltd)
Gujarat Themis Biosyn Ltd is a dynamic pharmaceutical company rooted in India, specializing in the meticulous manufacture of pharmaceuticals and crucial medicinal chemicals. Instea...d of merely producing drugs, Gujarat Themis Biosyn serves as a pivotal partner in the pharmaceutical supply chain, offering its extensive manufacturing capabilities on a job work basis to other entities operating within India. This model allows the company to maximize resource efficiency and contribute significantly to the wider availability of vital medicines throughout the region. By focusing on this area, Gujarat Themis Biosyn supports the healthcare ecosystem, enabling other companies to meet market demands without the burden of extensive in-house manufacturing infrastructure. The company’s product portfolio features an array of specialized pharmaceutical intermediates. Rifamycin-S takes center stage, a crucial component utilized in medications targeting a range of debilitating conditions. The portfolio includes Mycobacterium avium complex, leprosy, and Legionnaires’ disease. Additionally, they manufacture Rifamycin-O, essential for treating common ailments like traveler’s diarrhea and more complex disorders such as irritable bowel syndrome and hepatic encephalopathy. Gujarat Themis Biosyn also produces Lovastatin, a key ingredient in medicines aimed at managing cholesterol levels and promoting cardiovascular health. The company's dedication to producing these specialized ingredients highlights its role in contributing to both routine treatments and addressing critical health challenges. Established in 1981 and headquartered in Mumbai, Gujarat Themis Biosyn Ltd has cultivated a robust presence in the Indian pharmaceutical sector. Over the decades, the company has refined its manufacturing expertise and strengthened its commitment to quality and innovation. The company has positioned itself as a reliable source for bulk drug manufacturing and pharmaceutical intermediates, fostering trust and collaboration with its clients. The Mumbai headquarters serves as a central hub for overseeing its operations, guiding strategic decisions, and maintaining a steadfast commitment to improving health outcomes through pharmaceutical excellence.
Company Details
Key Leadership
Corporate Events
GUJTHEM Share Price: Frequently Asked Questions
What is the current share price of Gujarat Themis Biosyn Ltd?
Gujarat Themis Biosyn Ltd (GUJTHEM) trades at ₹379.85 on NSE and BSE. Market cap ₹4.45K (Cr). Educational data only.
What is the P/E ratio of Gujarat Themis Biosyn Ltd?
Gujarat Themis Biosyn Ltd has a P/E of 92.24x vs industry average 31.77x.
What is the Bull Run score for Gujarat Themis Biosyn Ltd?
Gujarat Themis Biosyn Ltd has a Bull Run score of 68.9/100 based on 25+ financial parameters.
Does Gujarat Themis Biosyn Ltd pay dividends?
Gujarat Themis Biosyn Ltd has a dividend yield of 0.16%. Past dividends don't guarantee future payments.
What is the ROE of Gujarat Themis Biosyn Ltd?
Gujarat Themis Biosyn Ltd has ROE of 21.69%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Gujarat Themis Biosyn Ltd?
Gujarat Themis Biosyn Ltd has debt-to-equity of 0.27.
Is Gujarat Themis Biosyn Ltd a good investment?
Bull Run gives Gujarat Themis Biosyn Ltd a score of 68.9/100. This is not investment advice — consult a SEBI-registered advisor.